OCC Quarterly Report | Quarter ended 30 June 2025

Orthocell has today released its Quarterly Report for the period ended 30 June 2025. This landmark quarter marks a transformational period for the Company following US FDA 510(k) clearance for Remplir™ and our successful entry into the world’s largest nerve repair market. Key highlights for the Quarter include:

• Record annual revenue of $9.19m for FY2025 – up 35.8% on the previous financial year
• Fifth consecutive quarter of record revenue – $2.73 million in the June ’25 Quarter
• Strong cash position of $28.7m with no debt
• US FDA 510(k) clearance received for Remplir™ opening the $1.6 billion US nerve repair market.
• Expanded regulatory approvals for Remplir in key international markets, including Hong Kong, Thailand and Canada.
• Continued global roll out of Striate+, with Brazilian regulatory approval received

Orthocell CEO and MD, Paul Anderson, said: “This was a landmark quarter for Orthocell following receipt of US FDA 510(k) clearance in early April. We were well prepared in advance of receipt of this approval, however once it came through, we were able to accelerate our progress towards first sales in the US. We couldn’t be more pleased with the progress achieved through the quarter, which culminated in the first US surgical use of Remplir at the end of June.” Click to read the ASX release.